Browse the evidence

Many racial and ethnic minority groups are under-represented in clinical trials of behavioral weight loss treatment.

Recognizing the under-representation of minorities can guide efforts to improve enrollment in clinical trials.

Biliopancreatic diversion (BPD) and mini gastric bypass (mini-GBP) have the highest diabetes remission rates among the surgical treatments analyzed.

Clinicians should consider BPD and mini-GBP as effective options for achieving diabetes remission in patients.

The results of the analysis should be interpreted with caution due to the minority representation of BPD and mini-GBP among bariatric surgeries.

Practitioners should be aware of the limitations in the data when recommending surgical options.

Further research with larger sample sizes is needed to confirm these results.

Practitioners should be aware that current findings are preliminary and require further validation.

INV-202 was well tolerated with no serious or severe treatment-emergent adverse events.

INV-202 appears to be a safe option for individuals with metabolic syndrome.

The number of people living with obesity has tripled worldwide since 1975.

Public health initiatives should address the rising obesity rates.

PLIN3 knockdown results in drastic reductions in lipid oxidation in myotubes from lean individuals.

Reducing PLIN3 may significantly impair lipid oxidation in lean muscle cells, which could impact metabolic health.

Only a small percentage of the studies reviewed used mobile platforms for interventions.

Future interventions may benefit from increased use of mobile technology.

There are few data that convincingly demonstrate significant reductions in risk of gastrointestinal cancers following weight-reducing strategies.

Practitioners should be cautious in expecting significant cancer risk reductions from weight loss interventions.

No dietary intervention was introduced during the experimental period.

The findings are solely attributed to the exercise intervention, emphasizing its effectiveness without dietary influence.

Higher sustained pharmacy costs were the main driver of the cost difference favoring MBS over GLP-1 receptor agonists.

Healthcare providers should consider ongoing medication costs when recommending obesity treatments.

Current methodologies for measurements of vascular markers need to be further standardized.

Practitioners should be aware of the variability in vascular marker measurements and the need for standardization.

Restrictive diets such as very-low-carb, ketogenic, very-low-calorie diets, and intermittent fasting have scarce evidence for direct benefit to NAFLD.

Practitioners should be cautious in recommending restrictive diets for NAFLD due to insufficient evidence of their benefits.

The random forest classification algorithm exhibits superior accuracy rates of 97% for Obesity_Type_I, 99% for Obesity_Type_II, and 83% for Obesity_Type_III compared to alternative classifiers.

Practitioners can utilize machine learning algorithms, particularly random forests, for more accurate obesity classification.

The study demonstrates the efficacy of machine learning methodologies in forecasting different forms of obesity.

Machine learning can be a powerful tool for predicting obesity, aiding in prevention and management strategies.

Maintaining or losing weight after becoming overweight or obese does not reduce the risk of coronary heart disease (CHD) or death.

Weight management strategies may not be effective for reducing CHD or mortality risk in this demographic.

There is no protective effect of weight loss on mortality risk.

Weight loss may not contribute to longevity in this population.

Tirzepatide does not seem to have a classical co-activating mode of action in humans.

Understanding the unique action of tirzepatide may inform treatment strategies for type 2 diabetes.

Sleeve gastrectomy has emerged as the most popular bariatric procedure in the last 10 years.

Surgeons should be aware that sleeve gastrectomy is currently the preferred option among patients.

Major advances have been made in understanding the molecular and cellular mechanisms regulating glucose entry into insulin-sensitive tissues.

Staying updated on these advances can inform treatment approaches for insulin resistance.

In patients with cardiometabolic HFpEF, semaglutide showed a 42% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Semaglutide may be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

Tirzepatide showed no meaningful benefit over semaglutide in reducing the risk of hospitalization for heart failure or all-cause mortality.

Clinicians may consider semaglutide as the preferred option over tirzepatide for this patient population.

Basal metabolic rate adjusted for body composition changes with gestational weight gain was not significantly different between high gainers and low+ideal gainers (151±33 compared with 129±36 kcal per day; P=.66).

Practitioners should note that increased weight gain does not necessarily correlate with increased basal metabolic rate when adjusted for body composition.

Greater male variation in basal energy expenditure may be explained by greater male variation in the size of energy-demanding organs.

Understanding organ size variation may help tailor nutritional strategies for energy expenditure.